DRAXIMAGE® MDP

DRAXIMAGE® MDP
The availability of technetium-based bone-seeking pharmaceuticals with improved soft-tissue clearance has led to sensitive, high-resolution images.

The skeleton is a complex system that performs several functions for the body including support, protection, movement, and blood formation via the blood marrow in some of the skeleton.

Radionuclide imaging of the skeleton is useful in the evaluation of osteoblastic abnormalities or altered osteogenesis involving bone and joints. This bone scintigraphy often provides an earlier, more sensitive diagnosis and often demonstrates more lesions than are found by common plain film radiographic procedures (metastatic disease, early osteomyelitis and avascular necrosis, stress fractures, occult fractures). Although the presence of a lesion on a bone scintigraphy can be non-specific in the absence of clinical information, its excellent sensitivity often provides important early recognition and direction for a complete differential diagnosis. The addition of a clinical history, clinical correlation or complementary studies adds considerably specificity that allows a more definitive evaluation and diagnosis.

Product Overview

Product name

Kit for the Preparation of Technetium Tc 99m Medronate Injection

Indications

Technetium Tc 99m Medronate Injection is a skeletal imaging agent used to demonstrate areas of altered osteogenesis as seen, for example, in metastatic bone disease, Paget’s disease, arthritic disease and osteomyelitis.

Description

The kit consists of reaction vials which contain the sterile, non-pyrogenic, non-radioactive ingredients necessary to produce Technetium Tc 99m Medronate Injection for diagnostic use by intravenous injection.
Available in kits containing 10 reaction vials.

Note

  • The recommended adult dose of Technetium Tc 99m Medronate Injection is 370 to 740 MBq (7.4 MBq/kg) [10 to 20 mCi (200 µCi/kg)] by slow intravenous injection over a period of 30 seconds.
  • Sufficient sodium pertechnetate is to be used for the reconstitution of a reaction vial to ensure that the dose of medronate administered does not exceed 10 mg.

PDF files

Product Monograph

MSDS

DISCLAIMER:

This information is not intended as medical advice. Responsibility for patient care resides with the healthcare professional on the basis of his or her professional license, experience and knowledge of the patient. For full Prescribing Information including indications, contraindications, warnings, precautions and adverse events, please see the appropriate product labeling.